Cortisol

Gastrointestinal (GI) perforation

Quality of Life as measured by the EQ5D

Overall response rate

28-day mortality

Salivary cortisol

hypotension

Neurocognitive Function

Assessment of the relative lactate level change over 24 hours

dosage and time on norepinephrine treatment

Amounts of intra-abdominal fat and total fat at the end of the treatment period for each cortisol dose.

Feasibility of Mindfulness Based Couples Therapy Intervention Among Breast Cancer Survivors and Their Partners (intervention adherence rate, defined as the proportion of sessions completed out of a total of 8 sessions)

Total body fat

To investigate the level of mitochondrial respiration after steroid administration

CAPS CGI

Change in PTSD symptom severity as assessed by the Clinician Administered PTSD Scale (CAPS)

Serum 17-OHP concentration in the morning

Study couldn´t start due to investigator

Participant evaluation of disease symptom intensity

ecological momentary assessments (EMA) of the Multidimensional Fatigue Inventory (MFI-20) General Fatigue scale, adjusted for EMA

immunologic markers, health care related quality of life, PTSD

The number of ovulatory menstruation in female patients

Mean Time to Itch Relief

28-Day All-Cause Mortality

To evaluate the response to a differentiated therapy (chemotherapy or allogeneic SCT) according to early bone marrow blast clearance and MRD levels in HR Ph- adult ALL patients.

Evidence of clinically definite ARDS confirmed by AECC criteria in 1994

Hyperglycemia

The primary endpoint was the hospital survival.

Prothrombin Fragment (PF1.2), a Marker of Thrombin Generation

Occurence of complications

The incidence of hemodynamic response, defined as a decrease in norepinephrine-equivalent dose with a MAP ≥65 mm Hg at 1 hour after initiation of angiotensin-II

Insulin resistance-Minimal Model (Si)

Efficacy of liquid powder containing tapioca starch stimutex AS, aloe barbadensis, rose hip oil and allantoin, compared to topical 1% hydrocortisone cream for the treatment of intertrigo.

Tolerability and acceptance of the two compounded oral hydrocortisone formulations

To establish whether acute β-blockade influences the ability to achieve airway reversibility and recovery with systemic corticosteroids and nebulised bronchodilators following histamine challenge in mild to moderate asthmatics.

Plasma insulin, glucose and C-peptide

State of Hypocortisolaemia when injected into deltoid muscle or thigh muscle

Radiographic Progression-Free Survival (rPFS)

Participants With "Controlled Disease" According to the Investigator's Global Assessment(IGA) of Disease Severity of the Face at Week 8 (Visit 6) in the Double-blind Phase

Survival Without Moderate/Severe Physiologic Bronchopulmonary Dysplasia (BPD)

Asparaginase-Related Toxicity Rate

Complete Remission Rate

In-hospital mortality

New or progressive multiple organ dysfunction syndrome as assessed utilizing the Pediatric Logistic Organ Dysfunction (PELOD-2) instrument.

Responder Status According to Pruritus Severity Score (Response = Mild or None in Pruritus Severity Score).

Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)

Time to Progression

Survival

Variation of acute kidney injury occurence between both groups

diminution of 50% of the proportion of patients with a score SOFA of 3 or 4

Change in concentration of Osteocalcin

Total cumulative dose of dopamine at 48 hours of study drug administration and by day 7 of life

Difference in hospital mortality in phase 1 vs phase 2 groups

Difference in RAVLT Total T-Score Between Treatments

28-day mortality after enrolment

Sequential Organ Failure Assessment (SOFA) Score at Baseline and 72 Hours

Incidence of nosocomial pneumopathy: radiological, clinical and bacteriological criteria

Area Under the Concentration Time Curve From Zero to 24 Hours (AUC0-24h) of Total S-cortisol in Plasma After Multiple Doses During Part A

Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy

Compare mean arterial blood pressure (MAP) change in the patients receiving hydrocortisone vs placebo

Remaining width of the attached gingiva

the peak neuron-specific enolase level

Composite adverse events of early versus conventional cessation of hydrocortisone

Incidence of Grade ≥ 2 stomatitis

Reduction in Swelling

To compare the impact of topical tacrolimus ointment to topical hydrocortisone cream by measuring inflammatory cytokine levels in the blood.

Minimal residual disease (MRD)-negativity rate in patients with T cell acute lymphoblastic leukemia

Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)

Comparison between subjective and objective acute stress experience in BPD Adolescents vs Healthy controls

Change from baseline in spider phobia symptoms / social phobia symptoms

Total Cerebral Volume as Measured by Volumetric Brain MRI

The Overall Response (OR) Rate (Complete Response + Incomplete Count Recovery + Partial Response)

Number of Patients With a Partial Response, Progressive Disease, or Stable Disease Based on Prostate-Specific Antigen (PSA) or Measurable Disease

Number of Participants Who Achieved a Second Decline in Prostate Specific Antigen (PSA) Following Progression on First Regimen

Overall Survival

response rate

Prostate Specific Antigen (PSA) Response (>50% Reduction From Baseline)

2-yr Overall Survival

response rate for patients with relapsed or refractory acute lymphoblastic leukemia after brief, high intensity chemotherapy

primary efficacy endpoint is all cause mortality

Color-Word Stroop Task

Efficacy of Hydrocortisone Ophthalmic Ointment 0.5% vs. Placebo for the reduction of signs and symptoms associated with allergic conjunctivitis

Incidence of Graft Versus Host Disease (GvHD)

Remission Re-induction (CR2) Rate

Early Postresuscitation Arterial Blood Pressure (mmHg) Measured Through Institution of Invasive Intra-arterial Pressure Monitoring (as Feasible).

To Determine the Recommended Phase II Dose (RP2D) of Ixazomib in Combination With DA-EPOCH-R.

Phenylephrine-mean arterial pressure dose-response relationship

PTSD assessed by the City Birth Trauma Scale

Side Effects AE's and SAE's

Occurrence of dose limiting toxicity (DLT) during cycle 1 of therapy

Pharmacokinetic parameters for serum cortisol - Maximum serum concentration (Cmax)

Maximum tolerated dose (MTD)

Area under the concentration time curve from time 0 to infinity (AUC0-inf) of Chronocort® to Cortef® based on baseline adjusted and unadjusted serum cortisol concentration calculated for each sampling time point.

primary PK endpoints

Maximum Serum Concentration (Cmax)

Frequency of Dose Limiting Toxicities of Palbociclib

Enrollment and completion of 60 infants

Rate of Toxicity in Study Participants Receiving Protocol Therapy

Maximum Tolerated Dose of EZN-3042

Occurrence of AF

Sadness-induced subgenual cingulate activity as measured by functional magnetic resonance imaging.

[C-11]NOP-1A Volume of Distribution Expressed Relative to Total Plasma Concentration